Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339410 | 0.89 | MAOB (0.81) | MAOBALDH1A1AKR1B1KDM4ESLC2A1 | |
| SCHEMBL22617461 | 0.86 | MAOB (0.76) | MAOBAKR1B1SLC2A1MAPK1TP53 | |
| SCHEMBL115442 | 0.85 | AKR1B1 (0.80) | MAOBALDH1A1AKR1B1SLC2A1MAPK1 | |
| SCHEMBL29495358 | 0.85 | AKR1B1 (0.80) | MAOBALDH1A1AKR1B1SLC2A1MAPK1 | |
| SCHEMBL4253616 | 0.85 | MAOB (0.74) | MAOBAKR1B1KDM4ESLC2A1MAPK1 | |
| SCHEMBL31634948 | 0.85 | MAOB (0.73) | MAOBALDH1A1KDM4EMAPK1HPGD | |
| SCHEMBL31619651 | 0.85 | MAOB (0.73) | MAOBALDH1A1KDM4EMAPK1HPGD | |
| SCHEMBL8251037 | 0.84 | MAOB (0.72) | MAOBAKR1B1SLC2A1MAPK1TP53 | |
| SCHEMBL2811962 | 0.84 | MAOB (0.72) | MAOBALDH1A1AKR1B1SLC2A1MAPK1 | |
| SCHEMBL8122629 | 0.84 | MAOB (0.72) | MAOBAKR1B1SLC2A1MAPK1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | MAOB 2043/4885ALDH1A1 3430/4885AKR1B1 1594/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MAOB 2147/4885ALDH1A1 3319/4885AKR1B1 1556/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | MAOB 2147/4885ALDH1A1 3319/4885AKR1B1 1556/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | MAOB 2147/4885ALDH1A1 3319/4885AKR1B1 1556/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | MAOB 2147/4885ALDH1A1 3319/4885AKR1B1 1556/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | MAOB 161/4885ALDH1A1 793/4885AKR1B1 2178/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | MAOB 2497/4885ALDH1A1 3734/4885AKR1B1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.